Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04793165
Other study ID # 5302
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 8, 2021
Est. completion date April 8, 2021

Study information

Verified date March 2021
Source Hospital Italiano de Buenos Aires
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot, interventional clinical trial to assess the effectiveness and safety of artificial pancreas (AP) using the ARG algorithm closed-loop system in a monitored 3-day period outpatient study. Once the safety of the device has been validated in the open-loop first 3-day period (continuous subcutaneous insulin infusion (CSII) plus continuous glucose monitoring (CGM)) the investigators will move the study to the second 3-day closed-loop period, without carbohydrate (CHO) counting.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date April 8, 2021
Est. primary completion date March 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patient has been diagnosed with T1DM at least two years ago and has been using an insulin pump and a CGM for at least 6 months prior to the trial first visit - Patient is >18 and <65 years - Patient has HbA1c < 10% - Woman in premenopausal age agrees to use contraceptive methods - Woman in premenopausal age has negative B-HCG in the tests performed in the trial - Patient is trained in CHO counting - Patient has signed informed consent and has the ability to understand the nature and intent of the study including the ability to comply with study procedures and is willing to keep scheduled visits Exclusion Criteria: - Patient has been hospitalized for diabetic ketoacidosis in the last 12 months - Patient has experienced severe hypoglycemia with loss of consciousness in the last 12 months - Patient has a history of coronary disease or cardiac failure - Patient with uncontrolled arterial hypertension - Patient with a condition that makes the researcher believe that it might increase the chance of hypoglycemia - Patient has symptoms compatible with active infectious disease - Patient has Cystic Fibrosis - Pregnant women, or women with the intention of getting pregnant; women breastfeeding - Patient has been hospitalized for psychiatric treatment in the last 6 months. - Patient with a diagnosis of adrenal disease - Patient has abnormal laboratory values for liver function: transaminase > 2x upper limit normal - Patient has abnormal laboratory values for renal function: GFR < 60 ml/min/1.73m2 - Patient has active gastroparesis - Patient is under oncological treatment - Patient has taken acetaminophen 72 hours previous to the study

Study Design


Intervention

Device:
Non-hybrid closed-loop system with ARG algorithm
To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting

Locations

Country Name City State
Argentina Hospital Italiano de Buenos Aires Buenos Aires

Sponsors (4)

Lead Sponsor Collaborator
Hospital Italiano de Buenos Aires Fundación Nuria/Cellex, Instituto Tecnológico de Buenos Aires, Universidad Nacional de La Plata

Country where clinical trial is conducted

Argentina, 

References & Publications (1)

Sánchez-Peña R, Colmegna P, Garelli F, De Battista H, García-Violini D, Moscoso-Vásquez M, Rosales N, Fushimi E, Campos-Náñez E, Breton M, Beruto V, Scibona P, Rodriguez C, Giunta J, Simonovich V, Belloso WH, Cherñavvsky D, Grosembacher L. Artificial Pancreas: Clinical Study in Latin America Without Premeal Insulin Boluses. J Diabetes Sci Technol. 2018 Sep;12(5):914-925. doi: 10.1177/1932296818786488. Epub 2018 Jul 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the effectiveness and safety of AP treatment without CHO counting in an outpatient setting. Percent of time in each range according to sensor glucose readings 3 days
Secondary To determine the percentage of time with glycemic levels from 70 to 180 mg/dl (time in range). Percent of time in the target range of 70-180 mg/dl according to sensor glucose readings 3 days
Secondary To determine, as a safety parameter, the percentage of time with glycemic levels less than 70 mg/dl. Percent of time in range of less than 70 mg/dl according to sensor glucose readings 3 days
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A